Background: Chronic kidney disease (CKD) is a broad term that refers to several conditions that impact the structure and function of the kidneys. Disease and management are classified according to stages of disease severity for patients with endstage renal disease (ESRD); hemodialysis becomes a crucial therapeutic intervention to sustain life by filtering waste products and excess fluids from the bloodstream.
Aim of study: This study aimed to assess the impact of hemodialysis (HD) on the levels of Activin and serum amyloid A in patients with chronic renal disease.
Materials and Methods: A study in Kirkuk City, conducted from November 2023 to April 2024, involved 70 chronic kidney disease patients undergoing regular hemodialysis at the Alamal dialysis centre. The study included 40 healthy individuals as a comparison group. Blood samples from both groups were examined for serum Activin and amyloid A levels using the EnzymeLinked Immunosorbent Assay.
Results: The study shows that Activin level was a highly significant increase (p < 0.01) in Hemodialysis patients before dialysis as compared to the control group. The mean Activin level in HD patients before dialysis was 3.104±1.172ng/ml, while in the control group, it was 1.745±0.068ng/ml. Similarly, HD patients exhibited significantly elevated levels of serum Amyloid A before dialysis as compared to the control group (p